Group 1 - The company has completed the cancellation of certain fundraising special accounts as part of its management strategy [1][2] - The total amount raised from the initial public offering (IPO) was RMB 1,913,072,420, with a net amount of RMB 1,806,750,318 after deducting issuance costs [1] - The company opened special accounts for the management and use of the raised funds in compliance with relevant laws and regulations [2] Group 2 - The decision to cancel the fundraising special accounts was made to facilitate management and reduce administrative costs [2] - The corresponding fundraising supervision agreements were terminated following the cancellation of the special accounts [2]

证券代码：688189 证券简称：南新制药 湖南南新制药股份有限公司 湖南南新制药股份有限公司 2024 年年度股东大会会议资料 《上 市公司股东会规则（2025 年修订）》以及《湖南南新制药股份有限公司章程》 《湖 南南新制药股份有限公司股东大会议事规则》等相关规定，特制定 2024 年年度 股东大会会议须知。 一、为保证本次大会的严肃性和正常秩序，切实维护与会股东（或股东代理 人）的合法权益，除出席会议的股东（或股东代理人）、公司董事、监事、高级 管理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他无关人员进 入会场。 二、出席会议的股东及股东代理人须在会议召开前半小时到会议现场办理签 到手续，并按规定出示股东账户卡、身份证明文件或营业执照复印件（加盖公章）、 授权委托书等，上述登记材料均需提供复印件一份，个人登记材料复印件须个人 签字，法定代表人证明文件复印件须加盖公司公章，经验证后领取会议资料，方 可出席会议。 会议开始后，由会议主持人宣布现场出席会议的股东人数及其所持有表决权 的股份总数，在此之后进场的股东无权参与现场投票表决。 三、会议按照会议通知上所列顺序审议、表决议案。 二〇二五年六月 ...

Fundraising Overview - The company raised a total of RMB 715 million by issuing 55 million shares at RMB 13.00 per share, with a net amount of RMB 699.14 million after deducting issuance costs of RMB 215.86 million [1] - The funds are managed in accordance with the company's fundraising management system and relevant regulations to protect investor interests [1] Fundraising Account Details - The company has opened fundraising accounts at several banks, including Shanghai Pudong Development Bank, China Minsheng Bank, and Ningbo Bank, for the management of the raised funds [2] - The company has also established accounts for its new investment project entities, including Intercity Connect (USA) Co., Ltd. and Gansu Shouyun Zhican Technology Co., Ltd. [2][3] Account Cancellation - The company has completed the cancellation of a fundraising account at China Minsheng Bank, which will no longer be used, and the corresponding tripartite supervision agreement has been terminated [3][4] - The cancellation of this account does not affect other fundraising investment projects and does not change the intended use of the funds or harm shareholder interests [4]

| 证券代码：605300 证券简称：佳禾食品 公告编号：2025-049 | | --- | | 佳禾食品工业股份有限公司 | | 关于签订募集资金专户存储四方监管协议的公告 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 | | 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | 一、募集资金基本情况 | | 中国证券监督管理委员会出具的《关于同意佳禾食品工业股份有限公司向特定对 | | 象发行股票注册的批复》（证监许可202570 号），同意公司向特定对象发行股 | | 票的注册申请。公司已向特定对象发行普通股（A 股）54,388,597 股，每股发行 | | 13.33 724,999,998.01 价格人民币 元，募集资金总额人民币 元。本次募集资金各 | | 项发行费用合计（不含增值税）人民币 13,909,476.44 元，扣除不含税的发行费 | | 用后，实际募集资金净额为人民币 711,090,521.57 元。上述资金到位情况经天衡 | | 会计师事务所（特殊普通合伙）审验，并于 2025 年 3 月 7 日出具"天衡验字（2025） | ...

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has decided to open a new special account for the management and use of raised funds due to changes in certain fundraising projects, ensuring compliance with relevant regulations and protecting shareholder interests [1][2]. Group 1 - The meeting of the 8th Supervisory Board was held on May 17, 2025, with three supervisors present, chaired by Mr. Tan Zhenyou [1]. - The Supervisory Board approved the proposal to open a special account for raised funds, aimed at standardizing the management, storage, and use of these funds [1]. - The decision was made after careful review and voting, with all three supervisors in favor, and no objections or abstentions [2]. Group 2 - The opening of the special account aligns with the regulatory requirements outlined in the "Guidelines for the Management and Use of Raised Funds by Listed Companies" and other relevant laws [1]. - The Supervisory Board confirmed that the new account does not harm the interests of shareholders, particularly minority shareholders [1].

上海克来机电自动化工程股份有限公司 募集资金使用管理制度 二○二五年五月修订 上海克来机电自动化工程股份有限公司 募集资金使用管理制度 上海克来机电自动化工程股份有限公司 募集资金使用管理制度 第一章 总则 第一条 为进一步规范上海克来机电自动化工程股份有限公司（以下简称"公 司"）募集资金的管理和使用，提高募集资金使用的效率，防范资金风险，确保资 金安全，切实保护投资者利益，根据《中华人民共和国公司法》 《中华人民共和国证 券法》《上市公司募集资金监管规则》《上海证券交易所股票上市规则》（以下简称 "《上市规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等有关法律、法规和规范性文件规定和《上海克来机电自动化工程股份有限公司章 程》（以下简称"《公司章程》"）的规定，结合公司实际情况，特制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性质的 证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划募集 的资金。 第三条 募集资金的使用应遵循集中管理、周密计划、预算控制、规范运作、公 开透明的原则。 第四条 公司募集资金应当按照招股说明书或者其他公 ...

第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金监管，但不包括公司实施股权激 励计划募集的资金监管。 第三条 募集资金到位后，按有关规定，公司应及时办理验资手续，由具有 证券从业资格的会计师事务所出具验资报告。 第四条 募集资金的使用应当符合招股说明书或者其他公开发行募集文件所 列用途使用。 第五条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集 资金，确保公司募集资金安全，不得操控公司擅自或变相改变募集资金用途。 第六条 公司控股股东、实际控制人及其他关联人不得直接或者间接占用或 者挪用公司募集资金，不得利用公司募集资金及募集资金投资项目(以下简称 "募投项目")获取不正当利益。 募集资金管理办法 上海耀皮玻璃集团股份有限公司 募集资金管理办法 （尚需提交公司2024年年度股东大会审议通过后生效） 第一条 为规范上海耀皮玻璃集团股份有限公司（以下简称"公司"）募集 资金的管理和使用，切实保护投资者的利益，提高募集资金的使用效率，根据 《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司募集资 金监管规则》、《上海证券交易所上市 ...

Group 1 - The company has completed the cancellation of its special account for raised funds, with a zero balance as of the announcement date [3] - The total amount raised through the non-public offering was RMB 832 million, with a net amount of RMB 821.67 million after deducting issuance costs [1] - The company has permanently supplemented its working capital with surplus funds from completed investment projects, totaling RMB 81.81 million and RMB 136.73 million from different projects [2][3] Group 2 - The company signed a tripartite supervision agreement with its sponsor and bank to manage the raised funds [2] - The investment project "Annual Production of 40,000 Tons of High-Performance Composite Short Fiber Production Line" has reached its intended usable state, leading to its completion [2] - The company has terminated the investment project "Annual Production of 80,000 Tons of Composite Short Fiber Production Line Upgrade Project" due to changes in market conditions [2]

上海凤凰企业（集团）股份有限公司 第六条 公司应当在募集资金到账后一个月内与保荐机构、存放募集资金的商业 银行（以下简称商业银行）签订募集资金专户存储三方监管协议。该协议至少应当包 括以下内容： （一）公司应当将募集资金集中存放于募集资金专户； 第三条 本制度适用于募集资金的存储、使用、变更、监督和责任追究。 第四条 公司的董事和高级管理人员应当勤勉尽责，督促公司规范使用募集资金， 自觉维护公司募集资金安全。 第二章 募集资金的存储 第五条 公司募集资金应当存放于经董事会批准设立的专项账户（以下简称募集 资金专户）集中管理。 募集资金专户不得存放非募集资金或用作其它用途。 募集资金管理制度 第一章 总 则 第一条 为规范上海凤凰企业（集团）股份有限公司（以下简称公司）募集资金 的管理与使用，保护投资者合法权益，根据《中华人民共和国公司法》《中华人民共 和国证券法》《上市公司证券发行管理办法》《上海证券交易所股票上市规则》《上 海证券交易所上市公司自律监管指引第1号——规范运作》《上市公司监管指引第2 号—上市公司募集资金管理和使用的监管要求》《上海凤凰企业（集团）股份有限公 司章程》（以下简称公司章程）等法律 ...

Core Points - The document outlines the management and usage of raised funds by Beijing Beilu Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations [2][3][4] - The company is required to ensure that the use of raised funds aligns with the commitments made in the prospectus and cannot change the intended use without shareholder approval [3][4][6] - The document specifies the establishment of special accounts for raised funds, which must be managed separately from other funds [4][5][6] Fund Management - The company must conduct verification of raised funds by a qualified accounting firm and disclose the status of these funds in annual reports [4][6][7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank where the funds are stored [6][7][8] - The company is required to ensure that raised funds are used for main business activities and cannot be used for high-risk investments or financial investments [9][10][11] Fund Usage - The company must follow the investment plan as stated in the issuance application and disclose any significant deviations from the plan [9][10][11] - Any changes in the use of raised funds must be approved by the board of directors and independent directors, and disclosed to shareholders [12][13][14] - The company must report on the progress of investment projects every six months and provide a special report on the use of raised funds [18][19][20] Fund Supervision - The internal audit department must check the status of raised funds at least quarterly and report findings to the board [36][37] - Independent directors can hire accounting firms to verify the use of raised funds if discrepancies are found [20][21] - Any violations in the use of raised funds that result in losses to the company will hold responsible personnel accountable [21][22]